Dexmedetomidine Sedation With Third Molar Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Intravenous sedation is used frequently for the relief of pain and anxiety associated with oral surgical procedures performed under local anesthesia. The purpose of this study is to learn about patient and surgeon satisfaction with sedation using Dexmedetomidine in combination with midazolam alone or with midazolam plus low dose ketamine while having wisdom teeth removed.
The sedation produced by dexmedetomidine is unique in that it mimics natural sleep, a unique quality not shared by other drugs. Dexmedetomidine is often used in anesthesia in hospital operating rooms and has been approved by the US Food and Drug Administration for the use planned in this study.
| Condition | Intervention | Phase |
|---|---|---|
|
Sedation |
Drug: Dexmedetomidine Drug: Midazolam Drug: Ketamine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Comparison of the Effectiveness of Sedation With i.v. Dexmedetomidine in Combination With Midazolam Alone or Midazolam and Low Dose Ketamine for Extraction of Third Molars. |
- Amnesia: recall of pictures shown during sedation, of local anesthetic injections, or of portions of the procedure. [ Time Frame: Recall for: pre-sedation, after dexmedetomidine load (4 minutes), during injections, and surgery (at 15 minute intervals during sedation) and immediately post surgery. Amnesia will be tested just prior to discharge and 24 hours following surgery. ] [ Designated as safety issue: No ]
- Respiratory Parameters: Respiratory rate, ETCO2, SpO2 [ Time Frame: Continuous. Recorded every 5 minutes or with any significant deviation from normal. ] [ Designated as safety issue: Yes ]
- Cardiovascular Parameters: Heart rate, blood pressure and ECG [ Time Frame: Continuous: Recorded at 5 minute intervals as well as any significant deviations from normal recorded. ] [ Designated as safety issue: Yes ]
- Surgeon satisfaction with sedation technique [ Time Frame: After surgery completed: day of surgery, within 15 minutes ] [ Designated as safety issue: No ]
- Patient satisfaction with sedation technique [ Time Frame: after completion of surgery (within 15 minutes) and the day after surgery (24 hours) ] [ Designated as safety issue: No ]
| Enrollment: | 19 |
| Study Start Date: | July 2009 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Dex plus midazolam
Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
|
Drug: Dexmedetomidine
Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
Other Name: Precedex
Drug: Midazolam
Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
Other Name: Versed
|
|
Active Comparator: Dex plus midazolam and ketamine
Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
|
Drug: Dexmedetomidine
Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
Other Name: Precedex
Drug: Midazolam
Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
Other Name: Versed
Drug: Ketamine
Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
Other Name: Ketalar
|
Detailed Description:
Subjects who have been screened medically and are scheduled for third molar surgery in the UNC OMFS clinic will be asked to volunteer for the study by the evaluating OMFS resident or attending physician. No additional x-rays will be taken other than those usually indicated for 3rd molar surgery. Informed consent will be obtained by study investigators.
Subjects will be instructed to fast for at least 8 hours prior to their appointment. Surgery will be performed in the Oral & Maxillofacial Surgery operating/sedation clinic where all monitoring equipment as well as emergency equipment is readily available, including the ability to ventilate the patient with oxygen (bag-mask), the ability to intubate, resuscitation drugs and equipment including a defibrillator. Patients will be positioned in a semi-reclining position in the dental chair and all monitors applied. A 20 gauge i.v. catheter will be placed and normal saline infusion attached. Supplemental oxygen will be administered via nasal cannula at 3 liters per minute. A picture will then be shown for recall testing. Pulse rate, arterial oxygen saturation (SpO2), respiratory rate, blood pressure, end-tidal CO2 (ETCO2), RSS sedation score and BIS value will be recorded as a baseline and at 5 minute intervals during the procedure. Any SpO2 values below 90% as well as any episodes of apnea greater than 20 seconds will be recorded. Monitoring and recording of all data will be done by one of the investigators. Data will be recorded on pre-printed data forms. The surgical procedure will be performed by an oral and maxillofacial surgery resident physician.
Following the administration of 0.12 mg/kg of dexamethasone , dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg. All of the above parameters will again be obtained and recorded. Patients will be randomly assigned by block randomization to receive either midazolam 0.04 mg/kg i.v. (50 patients), or midazolam 0.04 mg/kg plus 0.25 mg/kg of ketamine (50 patients). The operating surgeon and the patient will be blinded as to which protocol is being used. A dexmedetomidine infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery. At this point local anesthesia will be administered in all four quadrants. Pain reaction during injections will be recorded. When efficacy of local anesthesia has been confirmed, surgery will commence. The surgery will be interrupted at 15 and 30 minutes to show a picture for recall testing by an investigator. If at any point the patient is deemed to be uncomfortable or uncooperative due to inadequate sedation, the protocol will be broken and additional sedation administered as per usual standards. The rescue therapy may include additional midazolam, ketamine, narcotic or propofol at the discretion of the anesthetist/sedationist. At the conclusion of surgery the dexmedetomidine infusion will be discontinued and the patient will be attended by a recovery nurse for collection of postoperative data. During recovery the physiologic parameters will be recorded at 10 minute intervals. When the patient achieves a recovery Aldrete score of >9, they will be asked by an investigator to recall pictures for amnesia assessment, and asked to assess patient satisfaction before leaving with an escort. The patient will be contacted on the day following surgery by phone or e-mail by one of the investigators to test for recall of pictures shown (amnesia testing) and patient satisfaction
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- ASA physical status I and II
- Four asymptomatic third molars indicated for removal
Exclusion Criteria:
Clinical history or ECG evidence of:
- cardiac dysrhythmia or heart block
- ischemic heart disease
- asthma
- sleep apnea
- impaired liver, renal, or mental function
- chronic sedative or analgesic use
- allergies to any of the study drugs
- history of pericoronal infection with third molars
Contacts and Locations| United States, North Carolina | |
| University of North Carolina School of Dentistry | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Principal Investigator: | Jay A Anderson, DDS, MD | UNC Chapel Hill |
More Information
No publications provided
| Responsible Party: | Jay A. Anderson, DDS, MD, University of North Carolina at Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT01017237 History of Changes |
| Other Study ID Numbers: | 08-2157 |
| Study First Received: | August 14, 2009 |
| Last Updated: | April 23, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of North Carolina, Chapel Hill:
|
Dexmedetomidine sedation Oral surgery sedation Dexmedetomidine amnesia |
Additional relevant MeSH terms:
|
Ketamine Dexmedetomidine Midazolam Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents Adjuvants, Anesthesia Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Hypnotics and Sedatives GABA Modulators GABA Agents Analgesics, Non-Narcotic Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists |
ClinicalTrials.gov processed this record on May 22, 2013